论文部分内容阅读
多发性硬化(multiple sclerosis,MS)是一种中枢神经系统炎性脱髓鞘疾病,多发生于青壮年,是成人神经性致残的主要原因。传统治疗仅能延长疾病的缓解期,并不能彻底治愈。诱导性多能干细胞(induced pluripotent stem cells,i PSCs)具有干细胞的分化全能性,在MS细胞替代疗法中具有广阔的应用前景;而体细胞转分化技术相较于传统的i PSCs分化成少突胶质细胞谱系,缩短了时间窗,为MS治疗提供了一条新思路。随着获取神经干细胞和少突胶质细胞效率和质量的提高,未来的MS细胞治疗将有望取得重大的突破。
Multiple sclerosis (MS) is a central nervous system inflammatory demyelinating disease that occurs mostly in young adults and is the major cause of adult neurological disability. Traditional treatment can only prolong the remission of the disease, and can not be completely cured. Induced pluripotent stem cells (iPSCs) have the pluripotency of stem cells and have broad application prospects in MS cell replacement therapy. However, somatic cell transdifferentiation is less complicated than the traditional iPSCs Glial cell lineage, shortening the time window, provides a new idea for the treatment of MS. As the efficiency and quality of neural stem cells and oligodendrocytes increase, future breakthroughs in MS cell therapy are expected to make major breakthroughs.